1-3 of 3
Kathleen Hennessey
Close
Sort by
Journal Articles

Pilot Randomized Controlled Trial of an Educational Video for Chimeric Antigen Receptor (CAR)-T Cell Therapy Recipients

Patrick Connor Johnson, Tejaswini Dhawale, Richard Newcomb, Anna Barata, Kyle Karpinski, Mitchell Lavoie, Dagny Vaughn, Kathleen Hennessey, David Scheider, Hermioni L Amonoo, Angelo Volandes, Areej El-Jawahri
Journal: Blood
Blood (2023) 142 (Supplement 1): 255.
https://doi.org/10.1182/blood-2023-172776
Published: 2023
Journal Articles

Longitudinal Patient-Reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Patrick Connor Johnson, Tejaswini Dhawale, Mitchell W. Lavoie, Kyle Karpinski, Netana H. Markovitz, Kathleen Hennessey, Matthew Frigault, Areej El-Jawahri
Journal: Blood
Blood (2022) 140 (Supplement 1): 5232–5233.
https://doi.org/10.1182/blood-2022-163194
Published: 2022
Journal Articles

The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure.

Joan Blade, MD, Jesus San Miguel, MD, Arnon Nagler, MD, MSc, Pieter Sonneveld, MD, PhD, Andrew Spencer, DM, Tadeusz Robak, MD, PhD, Kathleen Hennessey, PharmD, Suneel D. Mundle, PhD, Sen H. Zhuang, MD, PhD, Jean-Luc Harousseau, MD, Robert Z. Orlowski, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 410.
https://doi.org/10.1182/blood.V110.11.410.410
Published: 2007